2023 Bayer-PCF Darolutamide Challenge Awards

The Prostate Cancer Foundation (PCF) and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Challenge Awards for novel investigator-initiated clinical investigations with correlative research for darolutamide in prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF and Bayer seek high-risk, currently unfunded projects from academic institutions in the United States (U.S. only). Bayer-PCF Challenge Awards: • Composed of a team of at least three (3) investigators from non-profit academic research centers in the U.S., including one young investigator (see PCF Challenge Award Team requirements below). • Support novel clinical investigations with correlative research for darolutamide in prostate cancer, over a duration of two years. • Provide up to a total of $1 million per team. Approximately $3 million will be designated for this award mechanism. • Cover only direct research costs and travel to the Annual PCF Scientific Retreat. • IRB submission and preferably approval is desired at time ofapplication. Research Proposals: • This RFP seeks proposals for novel investigator-initiated clinical investigations with correlative research for darolutamide in prostate cancer. A novel clinical trial must be part of the proposed research project. • Investigations may be in the following topic areas: o Novel clinical spaces for darolutamide in prostate cancer. o New combination treatment approaches with established or experimental drugs that capitalize on different mechanisms of action for eradication of prostate cancer. • Studies must include correlative research that aims to help better define biomarkers or other understandings that will improve the clinical use of darolutamide in patients with prostate cancer, to increase efficacy and/or quality of life. • All studies should include comprehensive statistical plans for clinical trial enrollment and power calculations. • All studies must include plans for enrolling diverse participant populations with appropriate representation of ethnic and racial minority groups. • Applications for trials testing combinations with non-Bayer assets may seek clinical trial support from other companies or organizations.